Theravance Biopharma, Inc. (TBPH)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Rick E. Winningham M.B.A. | Chairman & CEO | 1.3M | -- | 1960 |
Mr. Aziz Sawaf C.F.A. | Senior VP & CFO | 583.5k | -- | 1982 |
Mr. Stuart Knight | VP of IT&I and Chief Information Officer | -- | -- | -- |
Ms. Gail B. Cohen | Vice President of Corporate Communications & Investor Relations | -- | -- | -- |
Mr. Brett A. Grimaud Esq. | Senior VP, General Counsel & Secretary | -- | -- | 1974 |
Ms. Rhonda F. Farnum | Chief Business Officer and Senior VP of Commercial & Medical Affairs | 942.81k | -- | 1965 |
Ms. Stacy L. Pryce | Senior VP & Chief Strategy Officer | -- | -- | -- |
Dr. Aine Miller Ph.D. | SVP of Dev., VP of Regu., Quality, Clinical Safety & Pharmacovigilance and Head of Ireland Office | -- | -- | -- |
Theravance Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 99
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 05, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 01, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 28, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 26, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 08, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing